Keeping Track: Two Melanoma Approvals; Pfizer Discloses Retacrit Complete Response
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
New program gives free treatment with the checkpoint inhibitor for up to three years to patients taking 10 mg/kg dose as adjuvant therapy after surgery.
Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.
Acquisition is based on the prospects for Immunomedics’ Trodelvy, but regulatory changes, manufacturing challenges, and research dynamics could upset even the best-laid plans.